Editing Adenosine (section)

=== Supraventricular tachycardia ===
In individuals with [[supraventricular tachycardia]] (SVT), adenosine is a first line treatment used to help identify and convert the rhythm.<ref name="pmid39033975">{{cite journal |vauthors=Ciriello GD, Sorice D, Orlando A, Papaccioli G, Colonna D, Correra A, Romeo E, Esposito R, De Marco M, Diana V, Giordano M, Barrile LS, Russo MG, Sarubbi B |title=Antiarrhythmic therapy for narrow QRS supraventricular tachyarrhythmias in newborns and infants in the first year of life: Potent tools to be handled with care |journal=Indian Pacing and Electrophysiology Journal |volume=24 |issue=5 |pages=271–281 |date=2024 |pmid=39033975 |pmc=11480843 |doi=10.1016/j.ipej.2024.07.005}}</ref><ref>{{Cite journal | vauthors = Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K | title = Pharmacology of Adenosine Receptors: The State of the Art | journal = Physiological Reviews | volume = 98 | issue = 3 | pages = 1591–1625 | date = July 2018 | pmid = 29848236 | doi = 10.1152/physrev.00049.2017 | s2cid = 44107679 | doi-access = free | hdl = 11392/2391482 | hdl-access = free }}</ref><ref>{{Cite journal | vauthors = Delacrétaz E | title = Clinical practice. Supraventricular tachycardia | journal = The New England Journal of Medicine | volume = 354 | issue = 10 | pages = 1039–1051 | date = March 2006 | pmid = 16525141 | doi = 10.1056/NEJMcp051145 }}</ref><ref>{{Cite journal | vauthors = Belhassen B, Pelleg A | title = Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart: clinical and experimental aspects | journal = Journal of the American College of Cardiology | volume = 4 | issue = 2 | pages = 414–424 | date = August 1984 | pmid = 6376597 | doi = 10.1016/S0735-1097(84)80233-8 | s2cid = 21575090 | doi-access = free }}</ref>

Certain SVTs can be successfully terminated with adenosine.<ref name="pmid19000353">{{Cite journal | vauthors = Mitchell J, Lazarenko G | title = Wide QRS complex tachycardia. Diagnosis: Supraventricular tachycardia with aberrant conduction; intravenous (IV) adenosine | journal = CJEM  | volume = 10 | issue = 6 | pages = 572–3, 581 | date = November 2008 | pmid = 19000353 }}</ref> This includes any [[re-entrant arrhythmia]]s that require the AV node for the re-entry, e.g., [[AV reentrant tachycardia]] (AVRT) and [[AV nodal reentrant tachycardia]] (AVNRT). In addition, [[atrial tachycardia]] can sometimes be terminated with adenosine.<ref name="Goyal 2022">{{Cite book | vauthors = Goyal A, Basit H, Bhyan P, Zeltser R | chapter = Reentry Arrhythmia |date=2022| chapter-url= http://www.ncbi.nlm.nih.gov/books/NBK537089/|title = StatPearls|place=Treasure Island, FL |publisher=StatPearls Publishing|pmid=30725774|access-date=2022-01-28}}</ref>

Fast rhythms of the heart that are confined to the [[atrium (anatomy)|atria]] (e.g., [[atrial fibrillation]] and [[atrial flutter]]) or [[ventricle (heart)|ventricles]] (e.g., [[monomorphic ventricular tachycardia]]), and do not involve the AV node as part of the re-entrant circuit, are not typically converted by adenosine. However, the ventricular response rate is temporarily slowed with adenosine in such cases.<ref name="Goyal 2022" />

Because of the effects of adenosine on AV node-dependent SVTs, adenosine is considered a class V [[antiarrhythmic agents|antiarrhythmic agent]]. When adenosine is used to [[cardioversion|cardiovert]] an abnormal rhythm, it is normal for the heart to enter ventricular [[asystole]] for a few seconds. This can be disconcerting to a normally conscious patient, and is associated with angina-like sensations in the chest.<ref>{{Cite book|title=Coronary Pressure| vauthors = Pijls NH, De Bruyne B |year=2000|publisher=Springer|isbn=0-7923-6170-9 }}{{page needed|date=August 2019}}</ref>